WO2006062273A1 - Complement alimentaire d'acides amines ramifies - Google Patents
Complement alimentaire d'acides amines ramifies Download PDFInfo
- Publication number
- WO2006062273A1 WO2006062273A1 PCT/KR2005/000517 KR2005000517W WO2006062273A1 WO 2006062273 A1 WO2006062273 A1 WO 2006062273A1 KR 2005000517 W KR2005000517 W KR 2005000517W WO 2006062273 A1 WO2006062273 A1 WO 2006062273A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liv
- amino acids
- vitamin
- food
- weight
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 68
- 239000013589 supplement Substances 0.000 title description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 33
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 18
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 16
- 229960003080 taurine Drugs 0.000 claims abstract description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000310 isoleucine Drugs 0.000 claims abstract description 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004474 valine Substances 0.000 claims abstract description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 10
- 229920001202 Inulin Polymers 0.000 claims abstract description 10
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 10
- 235000013361 beverage Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 10
- 229940029339 inulin Drugs 0.000 claims abstract description 10
- 239000001259 polydextrose Substances 0.000 claims abstract description 10
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 10
- 229940035035 polydextrose Drugs 0.000 claims abstract description 10
- 239000001913 cellulose Substances 0.000 claims abstract description 9
- 229920002678 cellulose Polymers 0.000 claims abstract description 9
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000006049 herbal material Substances 0.000 claims abstract description 8
- 229940089491 hydroxycitric acid Drugs 0.000 claims abstract description 8
- 229960004203 carnitine Drugs 0.000 claims abstract description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 229930182816 L-glutamine Natural products 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940045999 vitamin b 12 Drugs 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 abstract description 25
- 229940024606 amino acid Drugs 0.000 abstract description 22
- 150000001413 amino acids Chemical class 0.000 abstract description 21
- 239000003797 essential amino acid Substances 0.000 abstract description 15
- 235000005911 diet Nutrition 0.000 abstract description 14
- 235000020776 essential amino acid Nutrition 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000037213 diet Effects 0.000 abstract description 8
- 244000068988 Glycine max Species 0.000 abstract description 5
- 235000010469 Glycine max Nutrition 0.000 abstract description 5
- 235000015278 beef Nutrition 0.000 abstract description 5
- 235000013601 eggs Nutrition 0.000 abstract description 5
- 235000013336 milk Nutrition 0.000 abstract description 5
- 239000008267 milk Substances 0.000 abstract description 5
- 210000004080 milk Anatomy 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 16
- 230000009469 supplementation Effects 0.000 description 13
- 229960003136 leucine Drugs 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 229960004295 valine Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 4
- 239000008047 antioxidant nutrient Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 235000001916 dieting Nutrition 0.000 description 4
- 230000037228 dieting effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 3
- 108010074084 Muscle Proteins Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- -1 amino acids Chemical compound 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
Definitions
- the present invention relates to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to: a health supplement food comprising branched chain amino acids (hereinafter, referred to as LIV) composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef and the like, and enhancing instant impact power under anaerobic conditions, via addition of L-glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthopanax; and a diet food or beverage further comprising dietary fibers such as inulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
- LIV branched chain amino acids
- LIV branche
- Important factors that should be considered in exercises include, firstly mind control to do exercise, secondly proper nutrition and thirdly sufficient rest.
- mind control to do exercise and taking sufficient rest can be solved by whether or not individual people make effort and make time for relaxation, but proper nutrition is another problem.
- Japanese Patent Laid-Open Publication No. Sho 60-049764 discloses a food composition for strengthening muscular power of an athlete, comprising amino acids composed of isoleucine:leucine:valine:arginine in a ratio of 1.3 to 0.6 : 1 : 0.4 to 0.8 : 1.4 to 0.6, and further proteins at a content of not less than 30%.
- Hei 9-052828 discloses an amino acid composition comprised essentially of leucine, wherein 5-20% by weight of valine, 5-20% by weight of leucine, 5-20% by weight of isoleucine, 3-20% by weight of lysine, 5-20% by weight of threonine, 3-20% by weight of methionine, 2-10% by weight of histidine, 1-10% by weight of phenylalanine, 1-10% by weight of tryptophan, 5-30% by weight of arginine, 5-30% by weight of glutamine and 2-10% by weight of proline are contained.
- WO 97/25883 discloses an amino acid preparation for stimulating hair growth, comprising the amino acids valine : leucine : isoleucine : proline in a ratio of 22:44:30:4.
- Korean Patent Laid-Open Publication No. 10-2003-0013836 published on Feb. 15, 2003, Application No.
- 10-2001-0048037 discloses a nutritional supplement food for sportsmen, comprising a mixture of powdered maltodextrin, fructose, glucose, protein, collagen (gelatin), taurine, L- glutamine, citric acid, glucosamine, vitamins, porcine chondroitin, Vegetable Wasps and Plant Worms (Cordyceps), L-carnitine, amino silk, Karamix, guar gum, Genevia, octacosanol, gardenia green and fruit flavor.
- Protein is one of particularly important nutrients for athletes and therefore athletes should ingest an adequate amount of protein.
- the reason why athletes should consume larger amounts of protein than ordinary people is to compensate for a break down of muscle into its original state and to induce active synthesis of protein at a recovery stage after performing exercise because protein is utilized as an energy source during exercise and particularly degradation of muscle protein is active and rapid for weight training.
- the present inventors have undertaken a great deal of research regarding composition of essential amino acids contained in a variety of foodstuffs and a minimum requirement of essential amino acids for infants, children and adults, respectively. Based on the results thus obtained, the present inventors have recognized the fact that absorption/digestion patterns of Koreans are dependent upon levels and composition of branched chain amino acids contained in dietary foods such as milk, eggs, soybean, beef, wheat and the like, rather than daily requirement of branched chain amino acids presented by Recommended Dietary Allowances (RDA) for Koreans and therefore have developed a supplement food in which branched chain amino acids are contained in compliance with an average ratio of branched chain amino acids contained in the above-mentioned foods.
- RDA Recommended Dietary Allowances
- the present inventors have developed a health supplement food for improving a weak constitution by adding herbal materials such as ginseng, red ginseng and Acanthopanax to branched chain amino acids, and have developed a health supplement food for dieting by addition of dietary fibers and appetite-related substances.
- the supplement food in accordance with the present invention can be utilized as a health supplement food that improves athletic ability of leisure and professional sportsmen enjoying or taking part in individual competition events such as golf, Taekwondo and martial arts.
- the supplement food in accordance with the present invention can be utilized as a health supplement food that enhances adaptability of ordinary people to intensity of physical labor and results athletes being able to train more, thereby enhancing quality of labor and improving quality of exercise.
- the supplement food in accordance with the present invention has effects regarding a decrease of blood glucose and increases amounts of amino acids in muscles and thereby can be utilized as a health supplement food such as a scientific nutritional agent for a diabetic.
- the supplement food in accordance with the present invention can be utilized as a health supplement food capable of overcoming a variety of disorders resulting from physical fatigue.
- the health supplement food for improving a weak constitution comprising herbal materials such as ginseng, red ginseng and Acanthopanax is expected to have effects on people in need of improvement of weak constitution, maintenance of a healthy body and improvement of body functions.
- the diet food or beverage further comprising dietary fibers such as inulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid is expected to have significant effects on people who desire to follow a dieting regimen, particularly via loss of body fat around the abdomen region.
- Fig. 1 is a graph showing serum levels of amino acids in the respective experimental groups obtained from studies in accordance with the present invention.
- FIG. 2 is a graph showing serum levels of amino acids in the respective experimental groups obtained from studies in accordance with the present invention. Best Mode for Carrying Out the Invention
- the diet beverage is comprised of 5.5% inulin dietary fiber (dietary fiber content: more than 90%), 5% xylitol, 3.4% polydextrose (dietary fiber content: more than 90%), 1.5% Garcinia cambogia bark extract powder (HCA: more than 50%), 0.5% citric acid, 0.40% L-leucine, 0.26% L-valine, 0.25% L-glutamine, 0.22% L-isoleucine, 0.13% taurine, 0.1% pineapple flavor, 0.05% vitamin C, 0.03% L-carnitine, 0.02% purified salt, 0.004% aspartame, 0.004% sucralose, 0.001% grapefruit seed extract (DF- 100), 0.001% vitamin Bl hydrochloride, 0.001% vitamin B2, 0.001% vitamin B6 hydrochloride, and 82.628% purified water, thereby making the total of 100%.
- the diet beverage containing dietary fibers as described above increases the quantity of amino acids in the muscle, inhibits absorption of fat, and activates intestinal motility by dietary fibers, which results in burning of abdominal fat and thus is helpful for dieting.
- LIV leucine
- I isoleucine
- valine which converts glucose of the liver and muscle into energy
- LIV comprises about 70% of muscle proteins and is consumed during prolonged intensive exercise as like glycogen.
- carbohydrates are known as an energy source that is primarily used when exercising, a great deal of attention has been directed to a LIV supplement known to offset against destruction of muscle proteins due to heavy exercise.
- an experimental protocol capable of eliciting exact results on studies of LIV, thus raising many different views.
- Many experts recognize the fact that an uptake of LIV after exercise has beneficial effects on recovery of physical strength.
- Leucine, isoleucine and valine should maintain balance between one another [41] [42] Leucine, isoleucine and valine are called branched chain amino acids as they are entangled like branched chains. In order to achieve key functions of these three essential amino acids, the most important is a balance and mixing ratio therebetween.
- the health supplement food utilizing branched chain amino acids in accordance with the present invention comprises LIV composed of 45% by weight of leucine, 25% by weight of isoleucine and 30% by weight of valine.
- the above-mentioned LIV may be composed of 45 to 47% by weight of leucine
- leucine decreases blood glucose and is utilized as a nutrient in wound healing, isoleucine is necessary for formation of hemoglobin, and valine converts glucose of the liver and muscle into energy.
- the total branched chain amino acid- supplemented food comprises 65-75% LIV
- a diet beverage by addition of dietary fibers such as inulin, polydextrose and crystalline cellulose to the LIV, or by addition of L- carnitine and hydroxy citric acid to the LIV.
- a health supplement food for improving a weak constitution by addition of herbal materials such as ginseng, red ginseng and Acanthopanax to the LIV
- L-glutamine promotes protein synthesis of muscles, prevents loss of muscles, accelerates a recovery rate of muscles, and assists in fast growth of muscles.
- L-glutamine is a free amino acid abundantly found in the body and comprises 60% of the total amino acids therein.
- L-glutamine is synthesized in the body by other amino acids, but is a conditionally-essential amino acid that must be ingested to maintain muscles and prevent a decline of physical strength in athletes since glutamine in muscles is quickly utilized when the body is exposed to stress due to physical training and exercise.
- Taurine is aminoethylsulfonic acid having properties of ampholyte like amino acids, and exhibits production of bile acid, regulation of cholesterol concentration, regulation of cell membrane ion permeability, anti-oxidative action and inhibition of excessive nerve excitation, as main physiological functions.
- Taurine is mainly found in cells of cardiac and skeletal muscles, brain and genital organs rather than in body fluid. Taurine has been known as a cardiotonic agent because it weakens contractive force of the heart when a concentration of calcium ions in the heart is below a normal level.
- taurine reacts with bile acid to form a polymer, thereby alleviating toxicity of bile acid, and assists in absorption of fats in the intestines.
- Taurine protects cells by removing peroxides and nitrogen oxides, and free groups before they damage the cell membranes. Taurine is most abundant among amino acids present in the brain, and also exhibits nervous sedative effects via inhibition of excessive nerve excitation when nerves are continuously excited, thereby diminishing stress due to exercise.
- the present invention has improved functions of the branched chain amino acid- supplemented food by adding L-glutamine and taurine, which are essentially required when exposed to excessive exercise, stress or overwork, to LIV.
- the branched chain amino acid- supplemented food has contained L-glutamine in an amount of 20 to 35% of the weight of LIV and taurine in an amount of 7 to 20% of the weight of LIV.
- Dietary fibers such as inulin, polydextrose and crystalline cellulose affect bacteria in the large intestine and therefore inhibit action of carcinogenic substances, thus preventing incidence of colon cancer. Those dietary fibers block absorption of cholesterol, thus preventing occurrence of adult diseases, alleviates the feeling of emptiness and retards absorption of foods, thereby filtering cholesterol. Dietary fibers combine with salts which are then discharged outside the body, thereby hindering elevation of blood pressure which is helpful for treatment and prevention of diabetes. Even for obese people, sufficient uptake of fibrous materials provides them a feeling of fullness while inhibiting absorption and digestion of nutrients, thus helping them refrain from excessive eating.
- L-carnitine is a coenzyme that plays an important role in fatty acid metabolism and is an amino acid derivative. Hydroxy citric acid suppresses appetite, assists in degradation of body fats and blocks synthesis of fats.
- the present invention has prepared a health supplement food for dieting by adding dietary fibers such as inulin, polydextrose and crystalline cellulose, and L-carnitine and hydroxy citric acid to LIV.
- dietary fibers such as inulin, polydextrose and crystalline cellulose, and L-carnitine and hydroxy citric acid
- Ginseng, red ginseng and Acanthopanax heighten vitality of the body and mind, thereby improving a weak constitution, are helpful for recovery from fatigue, activate production of blood in the body, thereby making blood circulation constant and favorable, improve functions or development of the body, calm and stabilize the mind and sprit, thereby strengthening functions of the heart, are useful in getting rid of neurasthenia, neurosis and stress, replenish the body fluid to appease thirst, are useful for strengthening functions of the spleen and diabetes, protect functions of the lung, thereby relieving coughing, assist in prevention and treatment of respiratory diseases, strengthen the stomach and intestines, thus promoting appetite, bind the bowel (stopping diarrhea), reinforce functions of the stomach and intestines, eliminate toxins in the body, thereby rendering rough skin fine and smooth, consequently being efficacious for skin diseases, and relieve furuncles, thereby resulting in detoxification and enhanced resistance against diseases.
- the present invention provides a health supplement food for improving a weak constitution, prepared by adding ginseng, red ginseng and Acanthopanax to LIV.
- vitamin C is important for synthesis of collagen (myofiber protein) of connective tissues and assists in absorption and digestion of minerals and iron constituting a cytochrome system which is involved in energy metabolism. Vitamin C removes histamine, a substance which is secreted in response to stress, and therefore plays a crucial role to control conditions of athletes who are tired from consecutive matches.
- Active oxygen species which are by-products produced during biological activity of the body, normally occur in energy production in the body, metabolic processes of lipids or proteins, catecholamine responses and a variety of inflammatory reactions, but most of them are neutralized by anti-oxidants.
- radicals and peroxides are known to play a very important role in pathogenesis of various diseases, i.e., cardiovascular diseases such as hypertension, arteriosclerosis and coronary artery diseases, malignant tumors, chronic inflammatory diseases, Parkinson's syndrome, epilepsy, various cerebral trauma, cataracts, skin cancers and auto-immune diseases.
- the active oxygen species generated by continuous prolonged exercises under the conditions at which athletes are subjected to heavy stress, lead to changes in fluidity, permeability and excitability of cell membranes or changes in functions of enzymes bound to the cell membranes.
- all of the materials constituting the body are susceptible to oxidative stress by active oxygen species, and representative examples of such materials include lipids, proteins, DNA, nucleic acids and enzymes. When those materials have suffered oxidative damage, this results in deterioration of cell functions.
- high intensity exercise require as much as 20 times more oxygen than an average oxygen demand of the muscle, sharply-elevated oxygen demand leads to hypoxia and accumulation of lactic acid, thereby causing fatigue of muscles.
- vitamins and minerals include vitamin A, vitamin C, vitamin B 1 hydrochloride, vitamin B2, vitamin B6 hydrochloride, vitamin B 12, vitamin D3, folic acid, nicotinic amide, calcium phosphate, iron, magnesium oxide, zinc oxide and maltodextrin.
- LIV 0 g/day administered, designated PSG placebo group
- HSG half-supplemented group
- FSG full- supplemented group
- the thus-supplied LIV was a supplement food containing 70% LIV/capsule and having a composition ratio of isoleucine, leucine and valine in a range of 1:1.8:1.2.
- Fig. 1 is for essential amino acids, whereas Fig. 2 is for non-essential amino acids.
- FSG exhibited 1,402.1+177.9 watt and 1,346.9+150.0 watt, respectively, and thus there was no difference between three groups.
- PSG exhibited 1,300.3+130.3 watt
- HSG and FSG exhibited 1,401.1+239.2 watt and 1,445.4+161.3 watt, respectively, and the maximum anaerobic power was significantly higher in FSG (P ⁇ 0.05).
- the maximum anaerobic power was significantly increased in FSG after supplementation of the LIV than before supplementation of the LIV (P ⁇ 0.01).
- HSG BCAA 2.5g/day Supplement Group
- a health supplement food utilizing branched chain amino acids in accordance with the present invention is needed by athletes and ordinary people.
- the health supplement food can be utilized to produce a health supplement food for improving a weak constitution, by inclusion of herbal materials such as ginseng, red ginseng and Acanthopanax, and to produce a diet food or beverage and particularly a food or beverage for removing body fat around the abdomen region, by further inclusion of dietary fibers such as inulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040103923A KR100549697B1 (ko) | 2004-12-10 | 2004-12-10 | 무산소 상태에서 순간적인 임팩트 파워를 증대 시키는 아미노산 건강기능식품 |
KR10-2004-0103923 | 2004-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006062273A1 true WO2006062273A1 (fr) | 2006-06-15 |
Family
ID=36578072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2005/000517 WO2006062273A1 (fr) | 2004-12-10 | 2005-02-25 | Complement alimentaire d'acides amines ramifies |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100549697B1 (fr) |
WO (1) | WO2006062273A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011045810A1 (fr) | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme |
WO2012005568A1 (fr) | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Composition nutritive de stimulation de synthèse de protéines musculaires |
WO2013124860A1 (fr) | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Formulation revitalisante puissante |
WO2015177805A1 (fr) | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combinaison de taurine et de raceméthionine pour le traitement de maladies hépatiques |
US9961932B2 (en) | 2013-06-10 | 2018-05-08 | N.V. Nutricia | Muscle preservation in overweight or obese adult during weight loss program |
CN111296843A (zh) * | 2020-03-03 | 2020-06-19 | 上海泓商生物科技有限公司 | 抗疲劳、运动型益生菌 |
CN113080463A (zh) * | 2021-04-23 | 2021-07-09 | 江苏金维氨生物工程有限公司 | 一种快速补充体能的粉剂 |
CN113475661A (zh) * | 2021-07-07 | 2021-10-08 | 攀枝花学院 | 多功能健身速溶固体饮料及其制备方法 |
CN113853212A (zh) * | 2019-06-03 | 2021-12-28 | 雀巢产品有限公司 | 恢复膳食补充剂 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2036552B1 (fr) | 2006-07-05 | 2018-08-08 | Kao Corporation | Inhibiteur de la sénescence |
CN112868956A (zh) * | 2021-01-27 | 2021-06-01 | 中央民族大学 | 一种多功能运动饮料及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0949764A (ja) * | 1995-08-08 | 1997-02-18 | Toshiba Corp | 注型絶縁物の非破壊検査方法 |
KR20030013836A (ko) * | 2001-08-09 | 2003-02-15 | 주식회사 파시코 | 스포츠인용 보조식품 |
-
2004
- 2004-12-10 KR KR1020040103923A patent/KR100549697B1/ko not_active IP Right Cessation
-
2005
- 2005-02-25 WO PCT/KR2005/000517 patent/WO2006062273A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0949764A (ja) * | 1995-08-08 | 1997-02-18 | Toshiba Corp | 注型絶縁物の非破壊検査方法 |
KR20030013836A (ko) * | 2001-08-09 | 2003-02-15 | 주식회사 파시코 | 스포츠인용 보조식품 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011045810A1 (fr) | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Compositions pharmaceutiques contenant de la taurine et de la race-méthionine pour le traitement de l'alcoolisme |
EP3120716A1 (fr) | 2010-07-07 | 2017-01-25 | N.V. Nutricia | Composition nutritionnelle destinée à stimuler la synthèse des protéines musculaires |
WO2012005582A1 (fr) | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Composition nutritionnelle destinée à stimuler la synthèse des protéines musculaires |
CN103079415A (zh) * | 2010-07-07 | 2013-05-01 | N.V.努特里西阿公司 | 用于刺激肌肉蛋白质合成的营养组合物 |
WO2012005568A1 (fr) | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Composition nutritive de stimulation de synthèse de protéines musculaires |
US10045999B2 (en) | 2010-07-07 | 2018-08-14 | N. V. Nutricia | Nutritional composition for the stimulation of muscle protein synthesis |
WO2013124860A1 (fr) | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Formulation revitalisante puissante |
US9961932B2 (en) | 2013-06-10 | 2018-05-08 | N.V. Nutricia | Muscle preservation in overweight or obese adult during weight loss program |
WO2015177805A1 (fr) | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combinaison de taurine et de raceméthionine pour le traitement de maladies hépatiques |
CN113853212A (zh) * | 2019-06-03 | 2021-12-28 | 雀巢产品有限公司 | 恢复膳食补充剂 |
CN111296843A (zh) * | 2020-03-03 | 2020-06-19 | 上海泓商生物科技有限公司 | 抗疲劳、运动型益生菌 |
CN113080463A (zh) * | 2021-04-23 | 2021-07-09 | 江苏金维氨生物工程有限公司 | 一种快速补充体能的粉剂 |
CN113475661A (zh) * | 2021-07-07 | 2021-10-08 | 攀枝花学院 | 多功能健身速溶固体饮料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20050034568A (ko) | 2005-04-14 |
KR100549697B1 (ko) | 2006-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006062273A1 (fr) | Complement alimentaire d'acides amines ramifies | |
Jäger et al. | International society of sports nutrition position stand: protein and exercise | |
US8168241B2 (en) | Performance-enhancing dietary supplement | |
US7638148B2 (en) | Drink composition and a method for composing a drink | |
US20080233245A1 (en) | Liquid nutrient composition for improving performance | |
US20030143311A1 (en) | Recovery drink formula and method | |
US20080317886A1 (en) | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness | |
CN101742999B (zh) | 以穿心莲内酯为有效成分的抗疲劳剂及口服组合物 | |
US7740878B2 (en) | Use of betaine to enhance exercise performance | |
CA2362344A1 (fr) | Composition pour optimiser la performance musculaire en cours d'exercice | |
CN106261220A (zh) | 一种含天然no源的果蔬饮料及其制备方法 | |
US20030104107A1 (en) | Energy drink formula and method | |
Ali et al. | Sports and exercise supplements | |
KR100463414B1 (ko) | 스포츠인용 보조식품 | |
RU2609813C1 (ru) | Функциональный пищевой продукт "Амино Джем" | |
Maheshwari et al. | Latent therapeutic gains of beetroot juice | |
Sanz et al. | Branched chain amino acids and sports nutrition and energy homeostasis | |
Leutholtz et al. | Optimizing nutrition for exercise and sport | |
US8367123B2 (en) | Supplement formula to prevent and deter muscle trauma and method of using same | |
JP7460327B2 (ja) | 経口組成物 | |
RU2306720C1 (ru) | Продукт "спортамин" для питания спортсменов | |
Burke | Branched-chain amino acids (BCAAs) and athletic performance | |
KR20220166894A (ko) | 두뇌활성화와 성장촉진기능을 강화한 생식화한 차의 조성물 | |
UA143083U (uk) | Функціональна композиція для збагачення харчових продуктів спеціального дієтичного споживання (для спортсменів) | |
JP2005348710A (ja) | そら豆健康増進食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05764886 Country of ref document: EP Kind code of ref document: A1 |